New hope for liver cancer: experimental drug targets tough cases

NCT ID NCT07310173

Recruiting now Disease control Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called AST-3424 in people with advanced liver cancer that has a specific marker (AKR1C3-high) and has worsened after immunotherapy. About 75 participants will receive either AST-3424 or a standard drug (regorafenib) to see which helps them live longer. The goal is to find a new option for patients who have run out of effective treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AST-3424 (an experimental drug given by IV infusion)
What this could lead to: If it works, this could offer a new treatment option for people with a specific type of advanced liver cancer that has stopped responding to immunotherapy.
What could go wrong: This is a mid-stage trial with only 75 participants, so results may not apply to everyone. The drug is still experimental, and side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Nanjing Tianyinshan Hospital
RECRUITING

Nanjing, Jiangsu, 211102, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.